Haj-Ali Saflo Okba, Hernández Guijo Jesús Miguel
Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, España.
Gastroenterol Hepatol. 2009 Aug-Sep;32(7):472-82. doi: 10.1016/j.gastrohep.2009.01.181. Epub 2009 Jul 17.
In this study we evaluated the pharmacologic costs of hepatitis C treatment, considering recommendations on both the duration of therapy and sustained virological response. With this aim, we analyzed relevant scientific articles published in the previous 10 years, considering the most common genotypes present in Spain. In this analysis, we estimated overall costs to be 1,636,524.58-1,761,365.73 euro and 1,794.586.39-1,917,013.73 euro with the use of pegylated interferon (PegIFN)-alpha-2a and PegIFN-alpha-2b, respectively. Sustained virological response was 59.18% and 64.58% respectively, with no significant difference between the two formulations. Finally, we assess the economic costs of the use of high-dose PegIFN-alpha-2a and ribavirin in patients with genotype 1 and treatment resistance (baseline HCV-RNA values > 800.000UI/ml, without early viral response at 12 weeks and weight > 85kg).
在本研究中，我们评估了丙型肝炎治疗的药物成本，同时考虑了治疗持续时间和持续病毒学应答的相关建议。为此，我们分析了过去10年发表的相关科学文章，并考虑了西班牙最常见的基因型。在该分析中，我们估计使用聚乙二醇化干扰素（PegIFN）-α-2a和PegIFN-α-2b时的总成本分别为1,636,524.58 - 1,761,365.73欧元和1,794,586.39 - 1,917,013.73欧元。持续病毒学应答率分别为59.18%和64.58%，两种制剂之间无显著差异。最后，我们评估了在基因型1和治疗耐药（基线HCV-RNA值> 800,000 UI/ml，12周时无早期病毒应答且体重> 85kg）的患者中使用高剂量PegIFN-α-2a和利巴韦林的经济成本。
